Insights


Minimal Residual Disease Assessment in Lymphoid Malignancies

August 29th 2017

The Evolving Landscape of Therapy for Follicular Lymphoma

August 15th 2017

AR-V7 Testing in Prostate Cancer

July 31st 2017

Optimal Therapeutic Management of Mantle Cell Lymphoma

July 26th 2017

Future Strategies in Kidney Cancer Treatment

July 17th 2017

The Evolving Landscape of Immunotherapy for NSCLC

July 13th 2017

Checkpoint Inhibitors in Head and Neck Cancer

July 7th 2017

Expert Perspective on Treatment of Polycythemia Vera

May 31st 2017

Managing Chemotherapy Toxicity for 5-FU and Capecitabine

May 30th 2017

Current Approaches in Advanced Non-Driver Lung Adenocarcinoma

May 12th 2017

New Treatment Regimens for Previously Treated Myeloma

April 28th 2017

Next-Generation Agents for ALK-Positive NSCLC

April 27th 2017

Molecular Testing and EGFR-Mutant Non-Small Cell Lung Cancer

April 24th 2017

Targeting Angiogenesis with Chemotherapy for Advanced Breast Cancer

April 19th 2017

Practical Guide on the Use of Immunotherapy in Melanoma

February 8th 2017

Treatment of ALK- or ROS1-Mutated Non-Small Cell Lung Cancer

January 31st 2017

TKI-Resistant Chronic Myeloid Leukemia

January 21st 2017

Acute Promyelocytic Leukemia (APL): Diagnosis and Treatment

January 17th 2017

Chronic Myeloid Leukemia: Refining the Use of BCR-ABL TKIs

January 13th 2017

The Era of Immunotherapy for Advanced Head & Neck Cancer Squamous Cell Carcinoma

December 22nd 2016